Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | FPR2 | P25090 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77444 | 0.86 | KMT2A (0.55) | KMT2AFPR2MAPK1MEN1ROCK2 | |
| SCHEMBL77064 | 0.86 | KMT2A (0.70) | KMT2AMAPK1MEN1ROCK2ROCK1 | |
| SCHEMBL91611 | 0.83 | FPR2 (0.55) | KMT2AFPR2MAPK1ROCK2ROCK1 | |
| SCHEMBL77328 | 0.81 | NPC1 (0.50) | KMT2AMAPK1MEN1ROCK2ROCK1 | |
| SCHEMBL2559922 | 0.81 | ROCK1 (0.80) | KMT2AMAPK1MEN1ROCK2ROCK1 | |
| SCHEMBL29311910 | 0.79 | KMT2A (0.53) | KMT2AMAPK1MEN1ROCK2ROCK1 | |
| SCHEMBL10068143 | 0.79 | FPR2 (0.58) | KMT2AFPR2MAPK1MEN1ROCK2 | |
| SCHEMBL77635 | 0.78 | KMT2A (0.70) | KMT2AMAPK1MEN1SMN1; SMN2NPC1 | |
| SCHEMBL77468 | 0.78 | CNR1 (0.55) | KMT2AMAPK1MEN1ROCK2ROCK1 | |
| SCHEMBL77629 | 0.78 | ROCK1 (0.68) | KMT2AMAPK1MEN1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129415-B2 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090192196-A1 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192196-A1 | Fungicide hydroximoyl-tetrazole derivatives | HAAO, HAO1, CYP51A1 | KMT2A 609/4885FPR2 3656/4885MAPK1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.